Comparative Pharmacology
Head-to-head clinical analysis: DENDRID versus TYZEKA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENDRID versus TYZEKA.
DENDRID vs TYZEKA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
Telbivudine is a synthetic thymidine nucleoside analogue with activity against hepatitis B virus (HBV). It is phosphorylated intracellularly to the active triphosphate form, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HBV DNA polymerase (reverse transcriptase).
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
600 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Terminal elimination half-life is approximately 15 hours (range 12-20 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal excretion accounts for approximately 60%.
Category C
Category C
Antiviral
Antiviral, Hepatitis B